Peak antifactor Xa activity produced by dalteparin treatment in patients with renal impairment compared with controls

Adam R. Shprecher, Angela Cheng-Lai, Eileen M. Madsen, Hillel W. Cohen, Mark J. Sinnett, Serena T. Wong, Henny H. Billett

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Study Objective. To evaluate the relationship between impaired renal function and antifactor Xa activity in patients receiving dalteparin. Design. Open-label prospective study. Setting. Inpatient and outpatient units of a large teaching hospital. Subjects. Eleven patients with renal impairment and 11 control subjects with normal renal function. Intervention. Subjects were administered dalteparin at a dosage of approximately 100 U/kg subcutaneously every 12 hours. Measurements and Main Results. Peak steady-state antifactor Xa levels were compared between the groups. Mean ± SD levels were similar for patients with and without renal impairment: 0.47 ± 0.25 and 0.55 ± 0.20 U/ml, respectively. A test of equivalency showed statistical significance (p=0.0001). Conclusion. No meaningful difference in peak antifactor Xa activity was found between patients with renal impairment and control subjects. To the extent that peak antifactor Xa levels can be used as markers for adjusting doses of dalteparin, these data suggest that such adjustments are not necessary for patients with renal impairment who are not receiving dialysis.

Original languageEnglish (US)
Pages (from-to)817-822
Number of pages6
JournalPharmacotherapy
Volume25
Issue number6
DOIs
StatePublished - Jun 2005

Fingerprint

Dalteparin
Kidney
Therapeutics
Teaching Hospitals
Inpatients
Dialysis
Outpatients
Prospective Studies

Keywords

  • Antifactor Xa
  • Dalteparin
  • Dosage adjustment
  • LMWH
  • Low-molecular-weight heparin
  • Renal impairment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Peak antifactor Xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. / Shprecher, Adam R.; Cheng-Lai, Angela; Madsen, Eileen M.; Cohen, Hillel W.; Sinnett, Mark J.; Wong, Serena T.; Billett, Henny H.

In: Pharmacotherapy, Vol. 25, No. 6, 06.2005, p. 817-822.

Research output: Contribution to journalArticle

Shprecher, Adam R. ; Cheng-Lai, Angela ; Madsen, Eileen M. ; Cohen, Hillel W. ; Sinnett, Mark J. ; Wong, Serena T. ; Billett, Henny H. / Peak antifactor Xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. In: Pharmacotherapy. 2005 ; Vol. 25, No. 6. pp. 817-822.
@article{0f6e19061161489ea69d376e4a4fd406,
title = "Peak antifactor Xa activity produced by dalteparin treatment in patients with renal impairment compared with controls",
abstract = "Study Objective. To evaluate the relationship between impaired renal function and antifactor Xa activity in patients receiving dalteparin. Design. Open-label prospective study. Setting. Inpatient and outpatient units of a large teaching hospital. Subjects. Eleven patients with renal impairment and 11 control subjects with normal renal function. Intervention. Subjects were administered dalteparin at a dosage of approximately 100 U/kg subcutaneously every 12 hours. Measurements and Main Results. Peak steady-state antifactor Xa levels were compared between the groups. Mean ± SD levels were similar for patients with and without renal impairment: 0.47 ± 0.25 and 0.55 ± 0.20 U/ml, respectively. A test of equivalency showed statistical significance (p=0.0001). Conclusion. No meaningful difference in peak antifactor Xa activity was found between patients with renal impairment and control subjects. To the extent that peak antifactor Xa levels can be used as markers for adjusting doses of dalteparin, these data suggest that such adjustments are not necessary for patients with renal impairment who are not receiving dialysis.",
keywords = "Antifactor Xa, Dalteparin, Dosage adjustment, LMWH, Low-molecular-weight heparin, Renal impairment",
author = "Shprecher, {Adam R.} and Angela Cheng-Lai and Madsen, {Eileen M.} and Cohen, {Hillel W.} and Sinnett, {Mark J.} and Wong, {Serena T.} and Billett, {Henny H.}",
year = "2005",
month = "6",
doi = "10.1592/phco.2005.25.6.817",
language = "English (US)",
volume = "25",
pages = "817--822",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Peak antifactor Xa activity produced by dalteparin treatment in patients with renal impairment compared with controls

AU - Shprecher, Adam R.

AU - Cheng-Lai, Angela

AU - Madsen, Eileen M.

AU - Cohen, Hillel W.

AU - Sinnett, Mark J.

AU - Wong, Serena T.

AU - Billett, Henny H.

PY - 2005/6

Y1 - 2005/6

N2 - Study Objective. To evaluate the relationship between impaired renal function and antifactor Xa activity in patients receiving dalteparin. Design. Open-label prospective study. Setting. Inpatient and outpatient units of a large teaching hospital. Subjects. Eleven patients with renal impairment and 11 control subjects with normal renal function. Intervention. Subjects were administered dalteparin at a dosage of approximately 100 U/kg subcutaneously every 12 hours. Measurements and Main Results. Peak steady-state antifactor Xa levels were compared between the groups. Mean ± SD levels were similar for patients with and without renal impairment: 0.47 ± 0.25 and 0.55 ± 0.20 U/ml, respectively. A test of equivalency showed statistical significance (p=0.0001). Conclusion. No meaningful difference in peak antifactor Xa activity was found between patients with renal impairment and control subjects. To the extent that peak antifactor Xa levels can be used as markers for adjusting doses of dalteparin, these data suggest that such adjustments are not necessary for patients with renal impairment who are not receiving dialysis.

AB - Study Objective. To evaluate the relationship between impaired renal function and antifactor Xa activity in patients receiving dalteparin. Design. Open-label prospective study. Setting. Inpatient and outpatient units of a large teaching hospital. Subjects. Eleven patients with renal impairment and 11 control subjects with normal renal function. Intervention. Subjects were administered dalteparin at a dosage of approximately 100 U/kg subcutaneously every 12 hours. Measurements and Main Results. Peak steady-state antifactor Xa levels were compared between the groups. Mean ± SD levels were similar for patients with and without renal impairment: 0.47 ± 0.25 and 0.55 ± 0.20 U/ml, respectively. A test of equivalency showed statistical significance (p=0.0001). Conclusion. No meaningful difference in peak antifactor Xa activity was found between patients with renal impairment and control subjects. To the extent that peak antifactor Xa levels can be used as markers for adjusting doses of dalteparin, these data suggest that such adjustments are not necessary for patients with renal impairment who are not receiving dialysis.

KW - Antifactor Xa

KW - Dalteparin

KW - Dosage adjustment

KW - LMWH

KW - Low-molecular-weight heparin

KW - Renal impairment

UR - http://www.scopus.com/inward/record.url?scp=19444373921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19444373921&partnerID=8YFLogxK

U2 - 10.1592/phco.2005.25.6.817

DO - 10.1592/phco.2005.25.6.817

M3 - Article

C2 - 15927900

AN - SCOPUS:19444373921

VL - 25

SP - 817

EP - 822

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 6

ER -